Save the date next month and RP

Posted:
26
August 2010

Save the date next month and RPL will see you for the American College of Clinical Pharmacologys (ACCP) 39th Annual Meeting taking place 12th to 14th September 2010 in Baltimore, Maryland.

The Annual Meeting will cover a wide array of topics such as international drug development and collaboration, pharmacometrics, pharmacogenomics, and specific sessions relating to biologics, nutraceuticals, and drug therapy in special populations, providing an ideal platform for scientists of various disciplines to meet and discuss areas of common interest.

We invite you to come down and see us at our booth that will be located in Harborside DE zone at the Baltimore Marriott Waterfront Hotel. In addition we are pleased to announce that Dr Jorg Taubel, MD., FFPM., Clinical Pharmacologist and Principal Investigator at Richmond Pharmacology, is due to present at the Annual Meeting where he will address two core topics of discussion, namely:

  • 132 - Repeated Dosing of Strontium Ranelate 4G Over 15 days Does Not Prolong QTC Interval in Healthy Volunteers
  • 133 - PET500 A Newly Formulated Tetracaine Product is Effective in Reducing Penile Sensitivity  

Dr Taubel�s presentation has been scheduled for Poster Session 2 on Monday, 13th September, 2010 from 6 PM � 7:30 PM and there are also a number of other learning activities in store, so be sure not to miss out on what is expected to be both an educational and rewarding conference.

For more information on the Annual Meeting click here for further details or click here to view the preliminary meeting program.

We look forward to seeing you next month in Baltimore!

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more